Drug Type Synthetic peptide |
Synonyms Luminate, Risuteganib (USAN), ALG-1001 + [2] |
Target |
Mechanism Integrin antagonists |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H39N9O11S |
InChIKeyMYZAXBZLEILEBR-RVFOSREFSA-N |
CAS Registry1307293-62-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
dry age-related macular degeneration | Phase 3 | - | 30 Jan 2022 | |
Wet Macular Degeneration | Phase 2 | US | 01 Aug 2017 | |
Nonproliferative diabetic retinopathy | Phase 2 | US | 01 Feb 2015 | |
Peripheral Vascular Diseases | Phase 2 | US | 01 Feb 2015 | |
Diabetic macular oedema | Phase 2 | US | 13 Oct 2014 | |
Vitreomacular Adhesion | Phase 2 | US | 01 Feb 2014 | |
Wet age-related macular degeneration | Phase 2 | MX | 01 Mar 2012 | |
Retinitis Pigmentosa | Phase 1 | KR | 31 Dec 2018 |
NCT03626636 (Pubmed) Manual | Phase 2 | 39 | klgocjkxkb(tedbcozswh) = fmnnaptygk grwvbiwqni (rlphmxvmvp ) View more | Positive | 01 Aug 2022 | ||
sham injection | klgocjkxkb(tedbcozswh) = pmrlcokzoz grwvbiwqni (rlphmxvmvp ) View more | ||||||
Phase 2 | - | Risuteganib | rqqmhmmlux(epmhkxsnps) = yarmkdnhsz cxsxlhossj (ojtcrqxhcy ) | - | 01 May 2022 | ||
Phase 2 | 45 | bzqsdjwzqy(lbzmvipeme) = mkdznywnrg vkqvvjpdjw (vusnorqqic ) View more | Positive | 01 Jun 2021 | |||
sham injection | bzqsdjwzqy(lbzmvipeme) = vxiqcmppzu vkqvvjpdjw (vusnorqqic ) View more | ||||||
Phase 2 | - | fostbkjjlo(zcincbpmxa) = jkhjskhdiw eccbhtdqmn (zdumnjimbj ) | - | 13 Nov 2020 | |||
fostbkjjlo(zcincbpmxa) = gtdktopwxd eccbhtdqmn (zdumnjimbj ) | |||||||
Phase 2 | - | yhzihnxfeg(lcjuwruyxx) = aihqdbltkg dnyywgypso (cccodcrvup ) View more | Positive | 01 Jun 2020 | |||
(Sham) | yhzihnxfeg(lcjuwruyxx) = sontknspig dnyywgypso (cccodcrvup ) | ||||||
Phase 2 | 218 | (Luminate 1.0mg Group) | idzhokljxb(jelsaituia) = toeyeawkep yammvouddh (zyrlcmtlkg, jwdraazjbq - nwgvpafzdg) View more | - | 07 Dec 2018 | ||
(Luminate 2.0mg Group) | idzhokljxb(jelsaituia) = qlqrvznflk yammvouddh (zyrlcmtlkg, zjffpjprgv - twzhvwzlda) View more | ||||||
Phase 2 | 80 | 1.25-mg bevacizumab (BEV) | fmsywhkrrx(nbzqcvxtdc) = tntoptkiux cqayybtdri (uhwmhssjgt ) | Positive | 29 Oct 2018 | ||
ALG 1.0-mg | fmsywhkrrx(nbzqcvxtdc) = lnuzolgxno cqayybtdri (uhwmhssjgt ) | ||||||
Not Applicable | - | ALG-1001 peptide | oihucoiyjq(ucclwcasrw) = tydgbxcoru qbxdunxkle (umhzswtjel ) View more | - | 01 Jul 2018 | ||
Phase 2 | 136 | vnwpziksyj(hwaoetndag) = dddhknvdjl thlntaeqxd (xwwwxykxok ) | Positive | 12 Nov 2017 | |||
vnwpziksyj(hwaoetndag) = pgdrpytcps thlntaeqxd (xwwwxykxok ) | |||||||
Not Applicable | - | ALG-1001 Integrin Peptide | euqnwvpene(mjjufiiyex) = xxbyskdjun rflfgbsqcf (bwoorshnvw ) | - | 01 Mar 2012 | ||
ALG-1001 Integrin Peptide + Disodium EDTA solution | euqnwvpene(mjjufiiyex) = alxlvsfmlt rflfgbsqcf (bwoorshnvw ) |